Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-02-01 DOI:10.2807/1560-7917.ES.2025.30.7.2500074

François Blanquart, Vincent Vieillefond, Benoit Visseaux, Claire Nour Abou Chakra, Marta C Nunes, Alexandra Jacques, Stephanie Haim-Boukobza, Laurence Josset, Valentin Wehrle, Guillaume Deleglise, Thomas Duret, Marie Anne Rameix-Welti, Bruno Lina, Vincent Enouf, Antonin Bal

引用次数: 0

Abstract

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.